Rajeshwari Sridhara

发表

Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion

Martin Posch, Khadija Rantell, Olga Marchenko, 2021, Statistics in Biopharmaceutical Research.

Bortezomib for the Treatment of Mantle Cell Lymphoma

Richard Pazdur, Robert Justice, Chia-Wen Ko, 2007, Clinical Cancer Research.

Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib

Richard Pazdur, Robert Justice, Christine Garnett, 2008, Clinical Cancer Research.

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy

Anuradha Ramamoorthy, Richard Pazdur, Kaushalkumar Dave, 2018, Clinical Cancer Research.

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Liang Zhao, Hui Zhang, Richard Pazdur, 2015, Clinical Cancer Research.

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer

S. J. Schrieber, Chao Liu, Richard Pazdur, 2017, Clinical Cancer Research.

Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials

Sumithra J. Mandrekar, Lori E. Dodd, Rajeshwari Sridhara, 2013, Clinical Cancer Research.

Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015.

Richard Pazdur, Rajeshwari Sridhara, R. Pazdur, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Gideon Blumenthal, Nina Ditsch, David Cameron, 2014, The Lancet.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Lawrence H. Schwartz, Donald A. Berry, Janis M. Taube, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.

Richard Pazdur, Rajeshwari Sridhara, R. Pazdur, 2005, The oncologist.

Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues

Rajeshwari Sridhara, R. Sridhara, Aloka G Chakravarty, 2008, Statistical methods in medical research.

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

Sean Khozin, Hui Zhang, Richard Pazdur, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accelerated approval and oncology drug development timelines.

Richard Pazdur, Robert Justice, Rajeshwari Sridhara, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

Edward S. Kim, Richard L Schilsky, Elizabeth Garrett-Mayer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.